Viva Biotech’s Subsidiary Passes Fourth FDA Inspection, Boosting Global Expansion

An update from Viva Biotech Holdings ( (HK:1873) ) is now available.

Viva Biotech Holdings announced that its wholly-owned subsidiary, Zhejiang Langhua Pharmaceutical Co., Ltd., has successfully passed a cGMP on-site inspection by the U.S. FDA. This marks the fourth successful inspection, underscoring the company’s adherence to FDA standards and bolstering its efforts to expand into the international market, thereby enhancing its competitiveness and future growth prospects.

More about Viva Biotech Holdings

Viva Biotech Holdings operates in the pharmaceutical industry, focusing on providing customized research, development, and production services to pharmaceutical enterprises worldwide. The company is committed to maintaining high standards in quality control and production environments, as evidenced by its compliance with FDA regulations.

YTD Price Performance: 125.58%

Average Trading Volume: 7,356,227

Technical Sentiment Signal: Sell

Current Market Cap: HK$4.16B

For an in-depth examination of 1873 stock, go to TipRanks’ Stock Analysis page.